Lee Biosolutions Inc. has expanded its line of biomarkers to include products used to track epithelial ovarian cancer, breast cancer and liver cancer.
Based in Brentwood, Lee Biosolutions collects biological materials — human saliva, semen, urine and vaginal secretions, among others — and produces finished proteins, enzymes, biologicals, immuno-reagents and antibodies for life science research and clinical diagnostic testing. The company’s core business is diagnostic and Lee Biosolutions sells proteins and enzymes to research labs like the Cleveland Clinic and pharmaceutical companies such as Abbott Laboratories.
Lee Biosolutions has developed a proprietary process to purify and test for novel cancer biomarkers. In addition to the new biomarkers, the company is expanding its production of the other biomarkers in its lineup.
Earlier this year, the company said it had developed a unique process for purifying the prostate cancer tumor marker PSA.
"We continue to increase supply of CA 19-9 which often is used with patients with pancreatic cancer, CEA tumor marker that helps predict the outlook in patients with colorectal cancer and CA 72-4 which is now used in ovarian, pancreatic cancer and cancers starting in the digestive tract," said Burton Lee, president of the company. "Current research has identified CYFRA 21-1 used as a marker for non-small cell lung cancer and Lee Biosolutions has increased supply of Beta 2 Microglobuilnwhich is used as a marker for multiple myelomas and chronic lymphocytic leukemia."
The products are raw finished proteins that are used in formulations in invitro diagnostic products and research.
Lee Biosolutions had revenue of $6 million last year.
No comments:
Post a Comment